A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
NCT06855823 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 33
Last updated 2025-03-04
Summary
This is a phase I/II clinical trial to evaluate the efficacy and safety of Golidocitinib combined with Pomalidomide for relapsed/refractory peripheral T-cell lymphoma.
Conditions
- Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Interventions
- DRUG
-
Golicitinib combined with Pomadomide
golidoctinib 150 mgqd, pomalidomide 2mg/3mg/4mgqd
Sponsors & Collaborators
-
Sun Yat-sen University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-01-14
- Primary Completion
- 2026-12-31
- Completion
- 2026-12-31
Countries
- China
Study Locations
More Related Trials
-
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150 ·Status: RECRUITING ·Phase: PHASE3
-
Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea
NCT03288974 ·Status: COMPLETED
-
Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib
NCT02158702 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma
NCT05378971 ·Status: RECRUITING ·Phase: NA
-
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
NCT02103335 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
NCT07018050 ·Status: RECRUITING ·Phase: PHASE2
-
Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma
NCT03487133 ·Status: COMPLETED ·Phase: PHASE2
-
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
NCT06514508 ·Status: RECRUITING ·Phase: PHASE3
-
The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients
NCT05802992 ·Status: UNKNOWN ·Phase: PHASE3
-
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
NCT01734928 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
NCT05236621 ·Status: UNKNOWN ·Phase: PHASE3
-
Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
NCT01745588 ·Status: COMPLETED ·Phase: PHASE2
-
S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT01055301 ·Status: WITHDRAWN ·Phase: PHASE2
-
SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
NCT02661022 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma
NCT01722305 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM
NCT06255847 ·Status: RECRUITING ·Phase: PHASE2
-
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
NCT01638936 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
NCT03029234 ·Status: COMPLETED ·Phase: PHASE3
-
An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma
NCT02726581 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
NCT02312258 ·Status: COMPLETED ·Phase: PHASE3
-
The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)
NCT03242460 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
NCT07297329 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma
NCT02811978 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
NCT01497093 ·Status: COMPLETED ·Phase: PHASE1